Jon Saxe

Mr. Jon Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (NASDAQ: VTGN), and Kyto Technology and Life Sciences (OTC: KBPH), as well as at the private companies Achelios Therapeutics, Aether Therapeutics, Arbor Vita, Arcuo Medical, Cancer Prevention Pharmaceuticals, and Trellis Bioscience. He was Chairman of SciClone (prior to being sold SCLN: NASDAQ), President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was Entrepreneur in Residence (E-I-R) at Institutional Venture Partners. From 1993 to 1995, Mr. Saxe was Principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic, and pharmaceutical companies. From 1989 to 1993, he was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Before that, Mr. Saxe was Vice President, Licensing and Corporate Development, and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years. Mr. Saxe received his BS degree in Chemical Engineering from Carnegie Mellon University, his JD degree from George Washington University School of Law, his Master of Laws degree from New York University School of Law, and a Certificate in Business Administration from Duke University.